Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HCW Biologics ( (HCWB) ) has provided an announcement.
On June 26, 2025, HCW Biologics Inc. announced that it had received formal notice from Nasdaq confirming its compliance with the Equity Rule for continued listing on the Nasdaq Capital Market. However, the company remains under a Panel Monitor until June 23, 2026, and must request a hearing to address any future non-compliance. On August 19, 2025, HCW Biologics was notified of non-compliance as of June 30, 2025, risking suspension of its securities from trading on Nasdaq unless a hearing is requested by August 26, 2025. The company plans to request a hearing to stay the suspension and is exploring options to regain compliance, though there is no assurance of success.
The most recent analyst rating on (HCWB) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.
HCW Biologics faces substantial financial challenges and bearish technical momentum, reflected in a low valuation score. However, recent corporate events, such as regaining Nasdaq compliance and strategic partnerships, offer some positive outlook for future recovery.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
Average Trading Volume: 138,246
Technical Sentiment Signal: Sell
Current Market Cap: $9.87M
For an in-depth examination of HCWB stock, go to TipRanks’ Overview page.